tirzepatide cardiovascular outcomes trial 2024

tirzepatide cardiovascular outcomes trial 2024 Frontiers New Science Suggests Semaglutide Improves

Name: tirzepatide cardiovascular outcomes trial 2024 Frontiers New Science Suggests Semaglutide Improves
Brand: www.keygrove.com
SKU: 41059442947
Price: 28.75 USD
Availability: InStock
Rating: 4.1962 (9 reviews)

SKU: 41059442947

4.2

EUR28.75 EUR67.75

Pay in 4 interest-free payments of $7.19 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Description

You may not be familiar with GLP-1 terminology, but Im sure youve heard of the brands

Author contributions Zheng Su and Dian Xiao contributed equally to this work

Tirzepatide is relatively new to market, only gaining FDA approval for weight loss (under Zepbound) in November 2023

A., Munshi, C., Lee, H

According to clinical trials and post-marketing surveillance, the most common gastrointestinal symptoms include nausea, vomiting, diarrhoea, constipation, abdominal pain, and bloating (also described as abdominal distension, dyspepsia, or flatulence in product information)